doi:10.36849/JDD.6031
3. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
5. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version-- EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277-2294.
6. Sun Pharma announces Japan MHLW approval of ILUMYA™ for the treatment of plaque psoriasis. Mumbai, India, and Tokyo, Japan: Sun Pharmaceutical Industries Ltd.; June 29, 2020. https://jp.sunpharma.com/ up_pdf/20200629161219_pdf.pdf. Accessed July 2, 2020.
7. Ilumya (Tildrakizumab-asmn) injection, for subcutaneous use. Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA, 2018. 2018.
8. ILUMETRI® (tildrakizumab). Summary of Product Characteristics. Industrias Farmac uticas Almirall, S.A, Barcelona, Spain. 2018.
9. ILUMYA™ (tildrakizumab). Australian product information. Sun Pharma ANZ Pty Ltd, Macquarie Park, Australia. 2019.
10. Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderateto- severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615-622.
11. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276-288.
12. Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(12):2305-2312.
13. Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605-617.
14. Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: A randomized clinical trial. JAMA Dermatol. 2018;154(3):309-316.
15. Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: A phase 3 randomized clinical trial. JAMA Dermatol. 2019.
3. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
5. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version-- EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277-2294.
6. Sun Pharma announces Japan MHLW approval of ILUMYA™ for the treatment of plaque psoriasis. Mumbai, India, and Tokyo, Japan: Sun Pharmaceutical Industries Ltd.; June 29, 2020. https://jp.sunpharma.com/ up_pdf/20200629161219_pdf.pdf. Accessed July 2, 2020.
7. Ilumya (Tildrakizumab-asmn) injection, for subcutaneous use. Full Prescribing Information. Sun Pharmaceutical Industries, Inc., Cranbury, NJ, USA, 2018. 2018.
8. ILUMETRI® (tildrakizumab). Summary of Product Characteristics. Industrias Farmac uticas Almirall, S.A, Barcelona, Spain. 2018.
9. ILUMYA™ (tildrakizumab). Australian product information. Sun Pharma ANZ Pty Ltd, Macquarie Park, Australia. 2019.
10. Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderateto- severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615-622.
11. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276-288.
12. Blauvelt A, Sofen H, Papp K, et al. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. J Eur Acad Dermatol Venereol. 2019;33(12):2305-2312.
13. Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605-617.
14. Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: A randomized clinical trial. JAMA Dermatol. 2018;154(3):309-316.
15. Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: A phase 3 randomized clinical trial. JAMA Dermatol. 2019.
AUTHOR CORRESPONDENCE
Danilo C. Del Campo MD FAAD doctor@chicagoskinclinic.com
